Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Prevail Partners LLC is a Philadelphia-based life sciences venture capital firm founded in 2008. The firm focuses exclusively on clinical-stage biotech and pharmaceutical companies, providing capital to promising life sciences ventures. Prevail Partners facilitates access to emerging medical technologies for partners seeking next-generation therapies and treatments.
As of June 2024, Prevail Partners remains active in the investment landscape, with a portfolio that includes five companies. The firm has not disclosed its fund size or assets under management, but it continues to target investments that align with its mission of improving public health through innovative medical technologies.
Prevail Partners has achieved notable milestones, including successful exits with companies like HemoGenyx and BriaCell Therapeutics, both of which have gone public. The firm’s commitment to supporting clinical-stage companies positions it as a key player in the life sciences sector.
Prevail Partners invests in clinical-stage companies within the life sciences sector, specifically targeting therapeutics, preventive treatments, medical devices, and diagnostics. The firm is dedicated to supporting innovations that can lead to significant advancements in healthcare. Its investment strategy is designed to bridge capital access to promising clinical-stage companies, aiming for attractive returns from scientific advances in life science fields.
The firm primarily focuses on the US market but also includes international portfolio companies. Prevail Partners seeks to partner with companies that demonstrate potential for significant impact in their respective fields, emphasizing the importance of scientific rigor and market viability in their investment decisions.
Prevail Partners has a notable portfolio that includes five companies, with a focus on life sciences and healthcare. The firm’s portfolio features:
These companies reflect Prevail Partners' commitment to advancing healthcare through innovative solutions and technologies.
Mary Schaheen - President of Prevail Partners, Mary has extensive experience in the life sciences sector. She has been instrumental in guiding the firm’s investment strategy and portfolio management. Her background includes significant roles in venture capital and healthcare, contributing to her expertise in identifying promising biotech opportunities.
Founders interested in pitching to Prevail Partners should prepare a comprehensive pitch deck that includes an overview of their business, market analysis, and scientific validation. While specific channels for submission are not provided, a direct approach through professional networks or introductions is recommended. Response times may vary, so patience is advised after submission.
As of June 2024, Prevail Partners has made recent investments, including a notable investment in Triple Hair, a company focused on haircare and health. The firm continues to actively seek opportunities within the life sciences sector, maintaining its commitment to supporting clinical-stage companies.
What are Prevail Partners' investment criteria?
Prevail Partners focuses on clinical-stage biotech and pharmaceutical companies, particularly those involved in therapeutics, preventive treatments, medical devices, and diagnostics. The firm seeks to invest in companies that demonstrate significant potential for advancements in healthcare.
How can founders pitch to Prevail Partners?
Founders interested in pitching to Prevail Partners should prepare a detailed presentation that outlines their business model, market potential, and scientific validation. While specific application channels are not disclosed, a well-structured pitch deck is essential.
What makes Prevail Partners different from other venture capital firms?
Prevail Partners distinguishes itself by focusing exclusively on clinical-stage companies within the life sciences sector. The firm not only provides capital but also offers strategic guidance and access to a network of industry experts, which is crucial for navigating the complexities of the life sciences landscape.
What is the geographic scope of Prevail Partners' investments?
The firm primarily focuses on the US market but also includes international companies in its portfolio. This geographic flexibility allows Prevail Partners to tap into a broader range of innovative life sciences ventures.
What is the typical check size for investments?
While specific check sizes are not disclosed, Prevail Partners invests in clinical-stage companies, which typically require substantial funding to advance their technologies and products through development stages.
What kind of post-investment involvement does Prevail Partners have?
Prevail Partners adds value to its portfolio companies by providing not only capital but also strategic guidance and access to a network of industry experts. This involvement helps companies navigate challenges and capitalize on opportunities in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.